Home>Topics>Companies>Johnson & Johnson

Johnson & Johnson JNJ

  1. All
  2. Commentary
  3. Video Reports
  4. Headlines
    1. UPDATE 3-Cardinal to buy J & J vascular technology unit Cordis for $1.9 bln

      Headlines

      Mon, 2 Mar 2015

      NEW YORK, March 2 (Reuters) - U.S. pharmaceutical and medical equipment maker Johnson & Johnson said on Monday it agreed to sell its Cordis vascular technology unit to Cardinal Health for $1.9...

    2. Cardinal to buy J & J vascular technology unit Cordis for $1.9 bln

      Headlines

      Mon, 2 Mar 2015

      NEW YORK, March 2 (Reuters) - Cardinal Health said on Monday that it would buy Johnson & Johnson 's Cordis vascular technology unit for $1.9 billion and that the acquisition would boost 2017 earnings by 20 cents per share.

    3. Cardinal Health Acquires Major Device Manufacturer; No Initial Change to Our Fair Value Estimate

      Commentary

      Mon, 2 Mar 2015

      Cardinal Health announced March 2 that it will acquire Cordis, a cardiology and endovascular device manufacturer from Johnson & Johnson for $1.9 billion. The transaction is expected to close at the end of 2015 and provide earnings accretion in 2017

    4. Global Home Healthcare Market - Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020

      Commentary

      Fri, 27 Feb 2015

      in the report include 3M Health Care, Bayer AG, Abbott Laboratories, Cardinal Health, Inc., GE Healthcare, Johnson & Johnson Services, Inc., Gentiva Health Services, Inc., Invacare Corporation, F. Hoffmann-La Roche Ltd., Phillips

    5. Compelling Financial Benefit in Valeant's Latest Buy

      Headlines

      Fri, 27 Feb 2015

      competitors, such as Novartis NVS , Abbott ABT , and Johnson & Johnson JNJ , but we still believe there will still be attractive ..... place with 10% share, but well behind market leader Johnson & Johnson and its 40% share. The four top firms control approximately

    6. South Carolina court orders J & J to pay $136 mln in Risperdal case

      Headlines

      Thu, 26 Feb 2015

      Feb 26 (Reuters) - South Carolina's Supreme Court ordered Johnson & Johnson to pay a penalty of $136 million, upholding a jury's finding that the drugmaker's Janssen unit had improperly marketed its anti-psychotic drug Risperdal and concealed its risks.

    7. UPDATE 2-Pharmacyclics mulls sale; J & J , Novartis interested - Bloomberg

      Headlines

      Wed, 25 Feb 2015

      Feb 25 (Reuters) - Cancer drug maker Pharmacyclics Inc is exploring a sale and has attracted interest from Johnson & Johnson and Novartis AG, Bloomberg reported.

    8. Pharmacyclics mulls selling itself; J & J , Novartis interested-Bloomberg

      Headlines

      Wed, 25 Feb 2015

      Feb 25 (Reuters) - Cancer drugmaker Pharmacyclics Inc is exploring a possible sale of the company and has attracted interest from Johnson & Johnson and Novartis AG, Bloomberg reported, citing people familiar the matter.

    9. UPDATE 1-Boston Scientific to pay J & J $600 mln to settle Guidant suit

      Headlines

      Tue, 17 Feb 2015

      Feb 17 (Reuters) - Medical device maker Boston Scientific Corp on Tuesday said it has agreed to pay $600 million to Johnson & Johnson to settle a long-running lawsuit over Boston Scientific's 2005 acquisition of rival Guidant.

    10. Fitch: Boston Scientific's Settlement Reduces Liability Risk but Also Liquidity

      Headlines

      Tue, 17 Feb 2015

      ratings are unaffected by its recent settlement with Johnson & Johnson ( NYSE : JNJ ) regarding litigation associated with BSX's acquisition ..... The settlement calls for BSX to pay $600 million to JNJ during 2015. BSX will make two $300 million dollar

    « Prev12345Next »
    Content Partners